Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Oct 11 2023

Full Issue

Mallinckrodt Bankruptcy Plan Approved, Cutting $1 Billion In Opioid Payouts

The manufacturer of branded and generic drugs had been seeking court approval for a restructuring and bankruptcy plan allowing its payout to settle the opioid crisis to be reduced along with other debts. Also in the news: Narcan vending machines, a bill to prevent opioid deaths, and more.

Drugmaker Mallinckrodt on Tuesday won court approval for a bankruptcy plan that cuts $1 billion from what it must pay opioid crisis victims, cancels existing equity shares, and trims nearly $2 billion in other debt. The Ireland-based company reached a relatively swift conclusion to its second Chapter 11, which began on Aug. 28, just 14 months after its previous bankruptcy concluded. (Knauth, 10/10)

This is a setback to governments and individual addicts who filed lawsuits seeking compensation from drugmakers for their role in the opioid crisis. The legal fight stretches back nearly a decade, when more than 3,000 lawsuits from states, Native American tribes and counties alleged the drugmakers, pharmacies and distributors played down the risk of painkillers and didn’t stem their flow. A few opioid manufacturers that lacked the funds to settle those thousands of lawsuits turned to bankruptcy to try to resolve them. (Saeedy, 10/10)

In news about overdose-reversal drugs —

D.C.'s harm-reduction vending machines have pumped out at least 2,800 distributions of Narcan, Fentanyl tests, and other protective items since a pilot program launched last spring. With opioid overdoses at an all-time high, more communities are investing in innovative and low-cost intervention efforts — like vending machines stocked with free medical supplies — to help save lives. (Spiegel, 10/10)

Â鶹ŮÓÅ Health News: Narcan, Now Available Without A Prescription, Can Still Be Hard To Get 

Last month, drugstores and pharmacies nationwide began stocking and selling the country’s first over-the-counter version of naloxone, a medication that can stop a potentially fatal overdose from opioids. It’s sold as a nasal spray under the brand name Narcan. Coming off a year with a record number of opioid-related overdose deaths in the United States — nearly 83,000 in 2022, according to the Centers for Disease Control and Prevention’s National Center for Health Statistics — community health workers and addiction medicine experts were hopeful that the arrival of Narcan on retail shelves might make it easier for people to get the medication. (Fortier and Leonard, 10/11)

More on the opioid crisis —

U.S. Sen. Amy Klobuchar said more needs to be done to hold social media companies responsible when fentanyl or contaminated drugs are sold through their services. Anastasia Shevtsova's family said she lost her life after buying some pills on the social media app SnapChat. Later that night, Olga noticed the light shining out from under her daughter’s door. She knocked, then opened the door. She found her cold on her bed, with her face turning blue. (Collins, 10/10)

The alert shared in Boulder a few weeks ago warned of a powdered form of fentanyl, its texture similar to drywall plaster, and its color pink or tan, like sand. Boulder law enforcement officers found it near a dead body. They told the county health department, which released the public health alert five days later. The University of Colorado posted the alert on its website and Facebook page the same day, warning students to beware of the deadly powder. This is what they wanted, the parents who have pushed CU and the rest of the state’s universities and colleges for two years to do more to protect students from fentanyl poisoning. (Brown, 10/9)

The first person to be convicted of a fentanyl-related murder was sentenced on Tuesday to 15 years in prison by a Placer County judge, KCRA reported. In July, Nathaniel Cabacungan, 21, pleaded guilty to second-degree murder following the death of a 15-year-old Northern California girl, which the Placer County District Attorney said was the first fentanyl murder conviction of its kind in the state. (10/10)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ